Preetesh Jain - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Preetesh Jain

Showing results (171-180 of 176) with videos related to

Pageof 18

Sort By:

You have reached the last page of results.This site can display upto 176 results.

Blood Advances|August 5, 2025

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.

Nature Medicine|March 14, 2023

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.

Blood|October 23, 2024

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapyRishika Prasad, Abdur Rehman, Lubna Rehman, et al.

Blood Advances|February 24, 2026

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.

Blood Advances|December 11, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.

Blood Cancer Journal|April 25, 2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.

Pageof 18

Search research articles

Showing results (171-180 of 176) with videos related to

Sort By:

Pageof 18

You have reached the last page of results.This site can display upto 176 results.

Blood Advances|August 5, 2025

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.

Nature Medicine|March 14, 2023

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.

Blood|October 23, 2024

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapyRishika Prasad, Abdur Rehman, Lubna Rehman, et al.

Blood Advances|February 24, 2026

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.

Blood Advances|December 11, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.

Blood Cancer Journal|April 25, 2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.

Pageof 18